Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 2
1997 1
2003 3
2004 1
2005 1
2007 1
2009 3
2010 4
2011 6
2012 6
2013 8
2014 13
2015 12
2016 15
2017 21
2018 19
2019 31
2020 30
2021 31
2022 31
2023 30
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

218 results

Results by year

Filters applied: . Clear all
Page 1
ASSESSMENT OF CELL SURFACE TARGETS IN METASTATIC PROSTATE CANCER: EXPRESSION LANDSCAPE AND MOLECULAR CORRELATES.
Ajkunic A, Sayar E, Roudier MP, Patel RA, Coleman IM, De Sarkar N, Hanratty B, Adil M, Zhao J, Zaidi S, True LD, Sperger JM, Cheng HH, Yu EY, Montgomery RB, Hawley JE, Ha G, Lee JK, Harmon SA, Corey E, Lang JM, Sawyers CL, Morrissey C, Schweizer MT, Gulati R, Nelson PS, Haffner MC. Ajkunic A, et al. Among authors: yu ey. Res Sq [Preprint]. 2023 Dec 19:rs.3.rs-3745991. doi: 10.21203/rs.3.rs-3745991/v1. Res Sq. 2023. PMID: 38196594 Free PMC article. Preprint.
To fully capitalize on the potential impact of drugs targeting surface proteins, detailed knowledge about the expression patterns of the target proteins in tumor tissues is required. In castration-resistant prostate cancer (CRPC), agents targeting prostate-specific …
To fully capitalize on the potential impact of drugs targeting surface proteins, detailed knowledge about the expression patterns of the tar …
Determining clinical perspectives and strategies for improving enrollment of minoritized communities in prostate cancer clinical trials.
Brady L, Lee JR, Yu EY, Lin D, Gore JL, Nelson PS, Shiely F, Nyame YA. Brady L, et al. Among authors: yu ey. Am J Clin Exp Urol. 2023 Oct 15;11(5):385-394. eCollection 2023. Am J Clin Exp Urol. 2023. PMID: 37941652 Free PMC article.
This study sought to assess the knowledge, attitudes, and practices of clinicians around equity and inclusion in prostate cancer clinical trial initiatives in the United States. METHODS: An anonymous, web-based questionnaire was administered via REDCap (Research Electronic …
This study sought to assess the knowledge, attitudes, and practices of clinicians around equity and inclusion in prostate cancer clin …
Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study.
Yu EY, Berry WR, Gurney H, Retz M, Conter HJ, Laguerre B, Fong PCC, Ferrario C, Todenhöfer T, Gravis G, Piulats JM, Emmenegger U, Shore ND, Romano E, Mourey L, Li XT, Poehlein CH, Schloss C, Appleman LJ, de Bono JS. Yu EY, et al. Eur Urol Oncol. 2023 Nov 6:S2588-9311(23)00224-9. doi: 10.1016/j.euo.2023.10.008. Online ahead of print. Eur Urol Oncol. 2023. PMID: 37940446 Free article.
BACKGROUND: Limited responses have been observed in patients treated with enzalutamide after disease progression on abiraterone for metastatic castration-resistant prostate cancer (mCRPC), but androgen receptor signaling impacts T-cell function. ...PATIENT SUMMARY: Pembrol …
BACKGROUND: Limited responses have been observed in patients treated with enzalutamide after disease progression on abiraterone for metastat …
Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma.
Petrylak DP, Eigl BJ, George S, Heath EI, Hotte SJ, Chism DD, Nabell LM, Picus J, Cheng SY, Appleman LJ, Sonpavde GP, Morgans AK, Pourhosseini P, Wu R, Standley L, Croitoru R, Yu EY. Petrylak DP, et al. Among authors: yu ey. Clin Cancer Res. 2024 Jan 5;30(1):63-73. doi: 10.1158/1078-0432.CCR-22-3627. Clin Cancer Res. 2024. PMID: 37861407 Free PMC article. Clinical Trial.
PURPOSE: Effective treatment of locally advanced or metastatic urothelial carcinoma (mUC) remains an unmet need. Antibody-drug conjugates (ADC) providing targeted drug delivery have shown antitumor activity in this setting. ...
PURPOSE: Effective treatment of locally advanced or metastatic urothelial carcinoma (mUC) remains an unmet need. Antibody-drug conjug …
The effect of cisplatin-based neoadjuvant chemotherapy on the renal function of patients undergoing radical cystectomy.
Ho MD, Black AJ, Zargar H, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Montgomery JS, Yu EY, Xylinas E, Kassouf W, Dall'Era MA, Vasdev N, Sridhar SS, McGrath JS, Aning J, Holzbeierlein JM, Thorpe AC, Shariat SF, Wright JL, Morgan TM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Black PC. Ho MD, et al. Among authors: yu ey. Can Urol Assoc J. 2023 Oct;17(10):301-309. doi: 10.5489/cuaj.8570. Can Urol Assoc J. 2023. PMID: 37851909 Free PMC article.
INTRODUCTION: Cisplatin-based neoadjuvant chemotherapy (NAC) is the standard of care for patients with muscle-invasive bladder cancer (MIBC) undergoing radical cystectomy (RC). Cisplatin, however, can induce renal toxicity. ...
INTRODUCTION: Cisplatin-based neoadjuvant chemotherapy (NAC) is the standard of care for patients with muscle-invasive bladder can
Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study.
Nakamura Y, Mizuno N, Sunakawa Y, Canon JL, Galsky MD, Hamilton E, Hayashi H, Jerusalem G, Kim ST, Lee KW, Kankeu Fonkoua LA, Monk BJ, Nguyen D, Oh DY, Okines A, O'Malley DM, Pohlmann P, Reck M, Shin SJ, Sudo K, Takahashi S, Van Marcke C, Yu EY, Groisberg R, Ramos J, Tan S, Stinchcombe TE, Bekaii-Saab T. Nakamura Y, et al. Among authors: yu ey. J Clin Oncol. 2023 Dec 20;41(36):5569-5578. doi: 10.1200/JCO.23.00606. Epub 2023 Sep 26. J Clin Oncol. 2023. PMID: 37751561 Free PMC article. Clinical Trial.
Genome-wide exploration of genetic interactions for bladder cancer risk.
Yu EY, Tang QY, Chen YT, Zhang YX, Dai YN, Wu YX, Li WC, Mehrkanoon S, Wang SZ, Zeegers MP, Wesselius A. Yu EY, et al. Int J Cancer. 2024 Jan 1;154(1):81-93. doi: 10.1002/ijc.34690. Epub 2023 Aug 28. Int J Cancer. 2024. PMID: 37638657
Although GWASs have been conducted to investigate genetic variation of bladder tumorigenesis, little is known about genetic interactions that may influence bladder cancer (BC) risk. By leveraging large-scale participants from UK Biobank, we established a discovery d …
Although GWASs have been conducted to investigate genetic variation of bladder tumorigenesis, little is known about genetic interactions tha …
218 results